Abstract
Background
Recent reports have indicated a rising incidence of gastric carcinoids. This study aimed to evaluate the incidence pattern of gastric carcinoids in two large population-based cancer registries.
Methods
The Florida Cancer Data System (FCDS), Florida’s statewide cancer registry, and the Surveillance, Epidemiology, and End Results (SEER) program were used. The study population was defined as all cases of gastric carcinoid identified in either database from January 1981 to December 2000. Descriptive statistics and age-adjusted incidence rates were calculated.
Results
There were 326 (FCDS) and 594 (SEER) cases of invasive gastric carcinoid during the 20-year study period. The mean age of the patients was 65 years (range, 21–96 years), and the male:female ratio was 1:1. The age-adjusted incidence rate in FCDS increased from 0.04 (per 100,000 age-adjusted to the 2000 U.S. standard population) to 0.18 in the year 2000. The estimated annual percentage change in incidence was 8.17 in FCDS and 9.17 in SEER (p < 0.05). A decrease in gastric cancer was noted during this same period (from 8.64 to 11.14 cases per 100,000 in FCDS and from 11.14 to 8.06 cases per 100,000 in SEER).
Conclusions
This study documented a statistically significant eight- or ninefold increase in the incidence of gastric carcinoids in two large databases. The temporal increase in incidence correlates with the introduction and widespread use of proton pump inhibitors since the late 1980s. Other explanations include improved detection with wider application of upper endoscopy. Further epidemiologic studies are warranted.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fritz A, Percy C, Jack A, et al. (2000) International Classification of diseases for oncology. World Health Organization, Geneva
Kleinbaum DG, Kupper LL, Muller KE (1988) Applied regression analysis and other multivariate methods. 2nd ed. PWS Kent Publishing Co., Boston MA pp 497–512
Larsson H, Carlsson E, Mattsson H, et al. (1986) Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Gastroenterology 90: 391–399
Lassen A, Hallas J, Schaffalitzky De Muckadell OB (2004) Use of antisecretory medication: a population-based cohort study. Aliment Pharmacol Ther 20: 577–583
Maggard MA, O’Connell JB, Ko CY (2004) Updated population-based review of carcinoid tumors. Ann Surg 240: 117–122
Maton PN (1991) Omeprazole. N Engl J Med 324: 965–975
Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97: 934–959
Modlin IM, Lye KD, Kidd M (2003) Carcinoid tumors of the stomach. Surg Oncol 12: 153–172
Nakata H, Matsui T, Ito M, et al. (1992) Cloning and characterization of gastrin receptor from ECL carcinoid tumor of Mastomys natalensis. Biochem Biophys Res Commun 187: 1151–1157
National Cancer Institute, Surveillance, Epidemiology, and End Results program. Retrieved at: http://www.seer.cancer.gov
Naunton M, Peterson GM, Bleasel MD (2000) Overuse of proton pump inhibitors. J Clin Pharm Ther 25: 333–340
Ono M, Sato H, Kazumori H, et al. (2003) Effect of a gastrin/cholecystokinin B receptor antagonist, S-0509, on the omeprazole-induced proliferation of gastric mucosa in rats. J Lab Clin Med 142: 364–371
Seer Stat 5.1.14. Retrieved at http://www.seer.cancer.gov/seerstat/
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hodgson, N., Koniaris, L.G., Livingstone, A.S. et al. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc 19, 1610–1612 (2005). https://doi.org/10.1007/s00464-005-0232-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00464-005-0232-4